RenovaCare products are under development and not approved for sale in the United States.

RenovaCare products are under development and not approved for sale in the United States.

Latest Test Results Bolster RenovaCare Strategy to Spray Stem Cells on Wounds and Burns for Rapid Healing

RenovaCare, Inc., today announced positive spray test results demonstrating that its novel SkinGun™ technology achieves exceptionally-uniform distribution of fluids with 200 times greater coverage than conventional methods. These outcomes are especially promising to scientists developing patented RenovaCare CellMist™ and SkinGun™ technologies* for spraying fluids containing a patient’s own stem cells onto burns and wounds for rapid scar-free healing.

New Study: RenovaCare SkinGun™ Ultra-Gently Sprays Human Stem Cells to Achieve ‘Gold-Standard’ Viability for Skin Regeneration

New York & Pittsburgh – May 3, 2016 – RenovaCare, Inc., (OTCQB: RCAR), a developer of novel medical grade liquid spray devices and patented CellMist™ and SkinGun™ technologies*, today announced favorable outcomes from laboratory studies conducted by Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité – Universitätsmedizin Berlin, one of the…

RenovaCare, Inc. Completes Engineering, Research, and Studies Required to File 510(k) Submission to the FDA for its Novel Medical-Grade Liquid Spray Device

New York & Pittsburgh – April 12, 2016 – RenovaCare, Inc., a developer of novel medical grade liquid spray devices and patented CellMist™ and SkinGun™ technologies* for isolating and spraying a patient’s own stem cells onto burns and wounds for rapid self-healing, today announced that the company has successfully completed the engineering, studies, and associated efforts…